|
|
|
| Orphan Drugs Market and Management |
| LI Min1, WU Ri-wei2 |
1. Food and Pharmaceutical Industry Construction Management Office, Wuhan Airport Economic and Technological Development Zone, Wuhan 430043, China;
2. Nanchang National High-Tech Industrial Development, Nanchang 330096, China |
|
|
|
Abstract Rare diseases, also known as "orphan diseases", refer to the diseases which have a very low morbidity. Most of orphan diseases are congenital disease or chronic disease, and they are often dangerous. With the improvement of public awareness, support of national policy and development of diagnosis and treatment technology, orphan drugs market has gradually developed. Sales of the orphan drugs increased year by year and several "heavy bombs" have arisen. The international pharmaceutical companies began to seize the orphan drugs market and intensified drug development. The number of orphan drugs under research and development is more than 500, which are mainly for rare cancer, hereditary diseases, neurological diseases, infectious diseases and autoimmune diseases. Developed countries and regions have mature management system and market of orphan drugs, but China is still relatively backward in this regard.The dilemmas of domestic orphan drugs market is analyzed and some suggestions for these dilemmas are puted for ward, hoping to promote the development of the domestic orphan drugs market.
|
|
Received: 14 December 2016
Published: 25 July 2017
|
|
|
|
|
[1] 田圆圆, 张象麟, 董江萍. 欧美孤儿药的研究与开发现状. 中国新药杂志, 2012, 21(8): 844-850. Tian Y Y, Zhang X L, Dong J P. Current situation of orphan drug research and development in the Europe and America. Chinese Journal of New Drugs, 2012, 21(8): 844-850.
[2] Food and Drug A dministration (FDA). Rare Diseases Take Spotlight in Annual Event. .http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm244408.htm.
[3] EvaluatePharma. 2015年孤儿药研发分析报告(I). 药学进展, 2016, 40(1):62-68. EvaluatePharma. Orphan Drug Report 2015(I). Progress in Pharmaceutical Science, 2016, 40(1):62-68.
[4] Brewer G J, Mich A. Drug development for orphan diseases in the context of personalized medicine. Trans Res, 2009, 154(6): 314-322.
[5] Sharma A, Jacob A, Tandon M, et al. Orphan drug: development trends and strategies. Pharm Bioallied Sci, 2010, 2(4): 290-299.
[6] 汤立达. 2015年 FDA批准的新药. 现代药物与临床, 2016, 31(2): 265-268. Tang L D. New drugs approved by FDA in 2015. Drugs & Clinic, 2016, 31(2): 265-268.
[7] 陈玲, 刘艳红, 邹栩, 等. 2015年全球重要治疗领域新药研究的最新进展. 中国新药杂志, 2016, 25(6): 601-638. Chen L, Liu Y H, Zhou X, et al. Overview of the latest progress of global new drug research in 2015. Chinese Journal of New Drugs, 2016, 25(6): 601-638.
[8] EvaluatePharma. 2015年孤儿药研发分析报告(Ⅱ). 药学进展, 2016, 40(2):145-155. EvaluatePharma. Orphan Drug Report 2015(Ⅱ). Progress in Pharmaceutical Science, 2016, 40(2):145-155.
[9] 孙赛男, 董江萍. 国外孤儿药现状分析及对我国的启示. 中国医药工业杂志, 2015, 46(10): 1146-1150. Sun S N, Dong J P. The orphan drug status analysis of overseas and its inspirations to China. Chinese Journal of Pharmaceuticals, 2015, 46(10): 1146-1150.
[10] 谷景亮, 鲁艳芹, 钟彩霞, 等. 国外罕见病药物政策发展现状对比分析. 卫生软科学, 2013, 27(7): 393-396. Gu J L, Lu Y Q, Zhong C X, et al. Comparative analysis to rare disease pharmaceutical policy development status in foreign countries. Soft Science of Health, 2013, 27(7): 393-396.
[11] 赵赢, 刘艾林, 杜冠华. 中国与美国罕见病药物政策对比分析. 中国新药杂志, 2016,25(1):31-49. Zhao Y, Liu ’ai L, Du G H. Comparative analysis of rare disease pharmaceutical policies of China and America. Chinese Journal of New Drugs, 2016, 25(1): 31-49.
[12] 彪巍, 肖永康, 陈任, 等. 我国罕见病患者社会支持研究. 医学与社会, 2012, 25(10): 53-55. Biao W, Xiao Y K, Chen R, et al. Study on social support of rare disease sufferers in China. Medicine and Society, 2012, 25(10): 53-55.
[13] 吴方, 周迎波, 崔茉莉. 国际环境下的我国孤儿药产业发展策略研究. 中国医药工业杂志, 2015, 46(4): 428-434. Wu F, Zhou Y B, Cui M L. Research of orphan drugs industry development strategy of China under The International Environment. Chinese Journal of Pharmaceuticals, 2015, 46(4): 428-434.
[14] 陈淼, 冯文化. 国内外孤儿药研发现状. 中国新药杂志, 2014,23(7):764-768. Chen M, Feng W H. Current situation of international and national research of orphan drug. Chinese Journal of New Drugs 2014, 23(7):764-768.
[15] 韩金祥, 崔亚洲, 周小艳. 罕见疾病研究现状及展望. 罕少疾病杂志, 2011, 18(1): 1-6. Han J X, Cui Y Z, Zhou X Y. Current status and prospect of the research on rare diseases. Journal of Rare and Uncommon Diseases, 2011, 18(1): 1-6.
[16] 田苗, 田红, 解学星, 等. 罕见病用药现状分析. 现代药物与临床, 2014, 29(7): 701-707. Tian M, Tian H, Jie X X, et al. The development of orphan drugs. Drugs & Clinic, 2014, 29(7): 701-707. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
